Jason Finkelstein, a doctor based in Texas, collaborated with a cardiovascular testing company in South Florida to submit ...
I’ve talked to so many educators, and I just don’t feel like this is making their lives easier,” said board member Liz ...
CMS launches its Medicare GLP-1 Bridge July 1, giving eligible Medicare Part D beneficiaries access to weight-loss GLP-1s at a $50 monthly copay through December 2027. For health systems and pharmacy ...
The Trump administration has authorized a test program to see if the cannabis compound can ease some symptoms and reduce health care costs among older patients. By Jan Hoffman The Trump administration ...
"We continue to make progress against our top priorities of maintaining strong margins, reducing our cost structure and moving the business towards sustainable profitability," said CEO, Secretary & ...
Neil Batlivala has spent seven years building a healthcare company that most of the tech industry has never heard of and that serves a patient population most of Silicon Valley ignores. But last month ...
The front-page Seattle Times article “WA patients agonize as Medicare AI program continues to delay care,” on April 27, addressed Medicare’s attempts to moderate care costs and reduce inappropriate ...
On April 23, 2026, the Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) ...
A financially sustainable solution for how to cover GLP-1 drugs for obesity remains elusive. The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 ...
The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on Jan.
The RAPID pathway is designed to accelerate access to certain FDA-designated Class II and Class III devices for people with Medicare coverage, CMS and FDA officials said. (Inna Knot/GettyImages) The ...
Medicare has delayed a program for older Americans that would've required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results